Klaus Wagner
Directeur Technique/Scientifique/R&D chez BOUNDLESS BIO, INC.
Fortune : - $ au 31/05/2024
Profil
Klaus W.
Wagner is currently the Chief Medical Officer at Boundless Bio, Inc. Prior to his current position, he served as the Chief Medical Officer & Executive Vice President at Inhibrx, Inc. from 2015 to 2022.
Dr. Wagner holds a doctorate degree from Friedrich-Alexander University of Erlangen-Nuremberg.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BOUNDLESS BIO INC.
-.--% | 28/03/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Klaus Wagner
| Sociétés | Poste | Début |
|---|---|---|
| BOUNDLESS BIO, INC. | Directeur Technique/Scientifique/R&D | 20/02/2022 |
Anciens postes connus de Klaus Wagner
| Sociétés | Poste | Fin |
|---|---|---|
| INHIBRX, INC. | Directeur Technique/Scientifique/R&D | 01/02/2022 |
Formation de Klaus Wagner
| Friedrich-Alexander University of Erlangen-Nuremberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BOUNDLESS BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Inhibrx, Inc.
 Inhibrx, Inc. BiotechnologyHealth Technology Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA. | Health Technology |
